Randomised, split-face study of a dermocosmetic cream containing Sphingobioma xenophaga extract and Neurosensine in subjects with rosacea associated with erythema and sensitive skin.

Introduction: Rosacea is a chronic inflammatory skin condition associated with erythema, inflammation and skin sensitivity.

Objectives: To assess the benefit of a dermocosmetic cream (DC cream) containing Sphingobioma xenophaga extract and soothing agent in adult females with rosacea-associated erythema and sensitive skin.

Materials And Methods: During phase 1, DC was applied twice daily on the randomized half-face and compared to usual-skincare (USC) for 28 days.

A dermocosmetic regimen is able to mitigate skin sensitivity induced by a retinoid-based fixed combination treatment for acne: Results of a randomized clinical trial.

Introduction: Topical retinoids cause retinoid-induced skin discomfort (RISD) mainly during the first weeks of use leading to noncompliance and premature treatment discontinuation. A dermocosmetic (DC) may help to reduce treatment-related signs and symptoms and improve adherence.

Objectives: To assess the benefit of a DC regimen compared to a routine skin care regimen (RC) by reducing RISD signs and symptoms induced by a retinoid/benzoyl peroxide fixed-drug combination in subjects with acne.

A Dermocosmetic Significantly Reduces the Frequency and Intensity of Facial Skin Intolerability and Sensitivity in Subjects with Skin Intolerant to Skin Care Products and Sensitive Skin.

Introduction: Intolerance to dermocosmetics is frequent in subjects with allergic contact dermatitis (ACD). A dermocosmetic (DC) was developed to restore the natural skin barrier, to reduce skin inflammation and to improve sensitive skin in ACD.

Objective: To assess the benefit of a DC in subjects with an allergic background and intolerance to cosmetic care, or with sensitive skin.